Handelsavisen
prelaunch
Companies Healthcare PRE.L
PR
PRE.L London Stock Exchange Pharmaceuticals & Medical Research

Pensana PLC

$59,60
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
-22,8 %
Net margin
Debt / equity
0,34
Beta
52w range
Volume
Day range
Prev close
$20,18
Open
$17,25
Next earnings
Ex-dividend
TR 1Y
About

Pensana PLC is a mining company focused on the exploration and development of mineral resources, primarily in the non-gold precious metals and minerals sector.

Business. Pensana PLC (PRE.L) is a health care company engaged in pharmaceuticals and medical research. The firm is headquartered in the United Kingdom and is primarily listed on the London Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target31,25

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
31,25
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
not yet wired
Profitability
-22,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PRE.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PRE.L. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Pensana PLC (PRE.L) is a health care company engaged in pharmaceuticals and medical research. The firm is headquartered in the United Kingdom and is primarily listed on the London Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Pensana PLC has a liquidity risk as indicated by a current ratio of 0.07, which is significantly below the industry median, suggesting a weak ability to meet short-term obligations. The company's liquidity position is further challenged by a negative free cash flow of -17,591,800 USD and a negative operating cash flow of -2,643,920 USD, both of which indicate a cash outflow from operations. The company's capital structure is characterized by a debt-to-equity ratio of 0.34, which is relatively low compared to industry peers, but the presence of long-term debt of 17,160,120 USD adds to the financial leverage.

    In terms of profitability, Pensana PLC is currently unprofitable, with a net income of -11,497,910 USD and an operating income of -11,457,910 USD. The return on equity of -0.2276 and return on assets of -0.1404 further confirm the company's poor performance relative to its equity and asset base. These metrics are well below the industry median, indicating that the company is underperforming in terms of generating returns for its shareholders and utilizing its assets efficiently.

    The company's revenue concentration is not explicitly detailed in the available data, but the absence of segment-specific revenue data suggests that Pensana PLC may be heavily reliant on a single geographic or product segment. This lack of diversification could expose the company to higher operational and market risks. The company's capital expenditure of -6,130,410 USD indicates ongoing investment in its operations, but the negative value suggests that the company is spending more on capital projects than it is generating in cash from operations.

    Looking at the growth trajectory, Pensana PLC is currently experiencing a decline in financial performance, as evidenced by the negative operating and net income figures. The company's outlook for the current fiscal year is not explicitly provided, but the negative cash flows and profitability metrics suggest a challenging period ahead. The absence of detailed revenue history makes it difficult to assess the company's historical growth, but the current financial indicators point to a period of contraction rather than expansion.

    The risk assessment for Pensana PLC highlights a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could limit its ability to fund operations and invest in growth opportunities. The low dilution risk suggests that the company is not currently issuing a significant number of new shares, which is a positive sign for existing shareholders. However, the company's financial performance and liquidity position remain a concern, and any further deterioration could increase the risk of dilution in the future.

    Recent events and filings for Pensana PLC are not detailed in the available data, but the company's financial performance and liquidity position suggest that it may be facing operational and financial challenges. The absence of recent events or transcripts does not provide additional insight into the company's strategic direction or management's response to these challenges. Investors and analysts should monitor the company's financial statements and any future filings for updates on its financial health and strategic initiatives.

    Key takeaways
    • Pensana PLC is currently unprofitable with a net income of -11,497,910 USD and an operating income of -11,457,910 USD.
    • The company has a weak liquidity position, as indicated by a current ratio of 0.07 and negative free and operating cash flows.
    • The company's return on equity and return on assets are significantly below the industry median, indicating poor performance.
    • Pensana PLC has a low dilution risk but a medium liquidity risk, with a negative net cash position after subtracting total debt.
    • The company's capital expenditure is negative, suggesting ongoing investment in operations but with a cash outflow.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $59,60
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $50.5M
    Net cash
    -$17.2M
    Current ratio
    0.1
    Debt / equity
    0.3
    ROA
    -14.0%
    ROE
    -22.8%
    Cash conversion
    23.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Consumer Health86,0 %
    disclosed · sec_xbrl · 2025-12-31

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)PRE 0,2% · rank #41 of 109

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs PRE · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    +73,8 vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    -14,4 vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    -126,8 vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    +38,5 vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    +52,3 vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    -24,1 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -3,88
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-23 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Segment revenue · next quarter
    No quarterly segment estimate
    Segment data is reported at full-fiscal-year granularity only — no quarterly segment split is forecast (a quarterly figure is never inferred from the annual). See the full-fiscal-year segment-revenue card below.
    Full fiscal year~1 year ahead
    Segment-revenue forecast · full fiscal year · native currency
    • Consumer HealthFY2026 — next full year (forecast) · projected off FY2025 close, as of 2025-12-31 · conf —81,8MFORECAST
    • Consumer HealthFY2025 — reported · conf —5,7MREPORTED
    Model estimate of reported / forward segment revenue in issuer-native currency. Confidence shown where the model calibrated it; "—" where not (never inferred).
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$29,00
    Mean$31,25
    Median$30,00
    High$36,00
    Spot$59,60
    −47.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE-22,8 %Above median
    D/E0,34Bottom quartile
    Cash Conv0,23Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 73 481 sh2 exercises · 2 grants3 insiders
    • VANDERVEEN DAVIDDirector · Restricted Stock Unit → Class A Ordinary Share, par value $0.0015 per shareDisposed 8 681exercise · 2026-06-15
    • Cheng Yin PanDirector · Restricted Stock Unit → Class A Ordinary Share, par value $0.0015 per shareDisposed 15 873exercise · 2026-06-15
    • Cheng Yin PanDirector · Restricted Stock Unit → Class A Ordinary Share, par value $0.0015 per shareAcquired 6 406grant · 2026-05-26
    • Lo Hoi ChunChief Financial Officer · Restricted Stock Unit → Class A Ordinary Share, par value $0.0015 per shareAcquired 91 629grant · 2026-05-19

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Pensana PLC Market data — financials · 2026-05-29

    Ownership & reference

    Leadership

    • Tim R. GeorgeChief Executive Officer, Executive Director

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $02 insiders · last 365d
    • VANDERVEEN DAVIDDirector · Class A Ordinary Share, par value $0.0015 per shareOther 6 944 · 2026-06-15
    • Cheng Yin PanDirector · Class A Ordinary Share, par value $0.0015 per shareOther 15 873 · 2026-06-15

    Short positioning

    665.8Kshares short+19.4% vs prior
    2.48days to cover
    42.5%short of daily vol
    1.7Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PRE.LCanonical
    London Stock Exchange · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)
    2026-06-28 03:45 UTCEARNINGSUpcomingForecast: fundamentals_forecast (365d)
    2026-06-28 03:45 UTCEARNINGSUpcomingForecast: fundamentals_forecast (365d)
    2026-06-28 03:45 UTCEARNINGSUpcomingForecast: fundamentals_forecast (365d)
    2026-06-28 03:45 UTCEARNINGSUpcomingForecast: fundamentals_forecast (365d)
    2026-06-15 00:00 UTCINSIDER4 insider transactions — 2026-06 2 derivative
    2026-06-15INSIDERVANDERVEEN DAVID transacted 6.9k sh Class A Ordinary Share, par value $0.0015 per share — Director
    2026-06-15INSIDERCheng Yin Pan transacted 15.9k sh Class A Ordinary Share, par value $0.0015 per share — Director
    2026-06-15INSIDERCheng Yin Pan disposed of 15.9k sh Restricted Stock Unit — Director
    2026-06-15INSIDERVANDERVEEN DAVID disposed of 8.7k sh Restricted Stock Unit — Director
    2026-06-10FILING6-K filing →
    2026-06-04FILING6-K filing →
    2026-05-26 00:00 UTCINSIDER2 insider transactions — 2026-05 2 derivative
    2026-05-26INSIDERCheng Yin Pan acquired 6.4k sh Restricted Stock Unit — Director
    2026-05-20FILING6-K filing →
    2026-05-19INSIDERLo Hoi Chun acquired 91.6k sh Restricted Stock Unit — Chief Financial Officer
    2026-05-14FILING6-K filing →
    2026-05-14FILING6-K filing →
    2026-05-07FILING6-K filing →
    2026-05-04FILING6-K filing →
    2026-04-30FILING20-F filing →
    2026-04-02FILING6-K filing →
    2026-03-06FILING6-K filing →
    2026-03-03FILING6-K filing →
    2026-02-18FILING6-K filing →
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage